Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin Effect on IL-6 in Advanced NSCLC
NCT01997775Phase 2Terminated
- Sponsor
- National Cheng Kung University Hospital
- Start
- Aug 2013
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liquid metformin (Aspargo Labs) in non-small cell lung cancer (NSCLC), sponsored by National Cheng Kung University Hospital. Primary endpoint: The change of plasma IL-6 level after the treatment with metformin at 12 weeks. Started Aug 2013; status: terminated.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01997775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01997775.